The 35th CINP World Congress of Neuropsychopharmacology

Presentation information

Print

[CINP2024] Poster Session

CINP2024 » Poster Session

Schizophrenia 1 - Clinical (1)

Fri. May 24, 2024 5:30 PM - 6:30 PM CINP Poster Session Hall (Lobby Gallery)

[P133] Factors associated with continuation of paliperidone palmitate 1-month formulation monotherapy in patients with schizophrenia.

*Tatsuro Marumoto1, Hiroshi Horio1, Hiroaki Kinoshita2, Natsuko Morita2, Tokiko Touma3, Kyoko Takebe2, Akihide Wakamatsu1 (1. Medical Affairs Division, Janssen Pharmaceutical K.K., 2. Drug Safety Surveillance Department, Japan Safety & Surveillance Division, Janssen Pharmaceutical K.K., 3. Statistics & Decision Sciences Japan, Janssen Pharmaceutical K.K.)

Keywords:paliperidone palmitate 1-month formulation, LAI monotherapy, schizophrenia

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.

Password